Intra-mammary distribution of transdermal telapristone versus oral telapristone: a randomized window trial in women undergoing mastectomy

Ended Awarded Last action

Contract number
HHSN26100003
Awardee
Awarding agency
Obligated
$885,373

Award facts

Opportunity
  • TORFPI Solicitation number
Contract value 94% obligated
  • $885,373.24 Current, with exercised options
  • $939,473.24 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC
AN12 Health R&D Services; Health Care Services; Applied Research
Set-aside
No set-aside
Competition
Full and Open Competition · 5 offers Multiple Award, Fair Opportunity
Pricing
Cost No Fee
Place of performance
Chicago, IL 60611, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00006 -$142,251
Change Order P00005 $0
Other Administrative Action P00004 $0
Change Order 3 $0
Exercise an Option 2 $173,283
Funding Only Action 1 $22,002
Original award $832,339

Quick answers

Who was awarded contract HHSN26100003?

HHSN26100003 was awarded to Northwestern University by National Cancer Institute (National Institutes of Health) on August 26, 2014.

How much is contract HHSN26100003 worth?

The government has obligated $885,373 on HHSN26100003. Its potential value, with all options, is $939,473.

Is contract HHSN26100003 an order under another contract?

Yes. HHSN26100003 is a delivery order under HHSN261201200035I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.

Was contract HHSN26100003 competed?

The extent of competition for HHSN26100003 was full and open competition. The government received 5 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award